NCT01313793 - A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Healthy Volunteers

Interventions

DRUG

Treatment A-B

Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.

DRUG

Treatment B-A

Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels